1-2 of 2
Philippe Quitet, MD
Close
Sort by
Journal Articles

First Line Treatment with the R-VAD+C Regimen Followed by ASCT for Patients under 65 with a Mantle Cell Lymphoma (MCL). From the GOELAMS Group.

Remy Gressin, MD, Sylvie Caulet Maugendre, MD, Ghandi Damaj, MD, Noel-Jean Milpied, MD, Delphine Senecal, MD, Mathilde Hunault Berger, MD, Abdrrazak El Yamani, MD, Herve Maisonneuve, MD, Olivier Tournilhac, MD, Philippe Solal Celigny, MD, Philippe Quitet, MD, Pierre Feugier, MD, Cachera Choufy, MD, Jean Fontan, MD, Martine Escoffre Barbe, MD, Jerome Cornillon, MD, Annie Lemevel, MD, Claude Martin, MD, Philippe Moreau, MD, Philippe Colombat, MD
Journal: Blood
Blood (2006) 108 (11): 4694.
https://doi.org/10.1182/blood.V108.11.4694.4694
Published: 2006
Journal Articles

The VIP-ABVD Regimen Is Not Superior to the CHOP 21 for the Treatment of Non Epidermotropic Peripheral T Cell Lymphoma. Final Results of the “LTP95” Protocol of the GOELAMS.

Remy Gressin, MD, Michel Peoch, MD, Eric Deconinck, MD, Philippe Casassus, MD, Bernard Desablens, MD, Delphine Senecal, MD, Philippe Quitet, MD, Jean Pierre Vilque, MD, Charles Foussard, MD, Houchingue Eghbali, MD, Jerome Jaubert, MD, Olivier Tournilhac, MD, Virginie Lucas, MD, Vincent Delwail, MD, Bachera Choufi, MD, Antoine Thyss, MD, Francoise Huguet, MD, Frederic Maloisel, MD, Bruno Richard, MD, Noel-Jean Milpied, MD, Philippe Colombat, MD
Journal: Blood
Blood (2006) 108 (11): 2464.
https://doi.org/10.1182/blood.V108.11.2464.2464
Published: 2006